Want to take quizzes and track your credits?
The SARS-CoV-2 pandemic has severely affected international travel. With efficacious COVID-19 vaccines available, Qatar implemented a pilot program between February 18 and April 26, 2021, to ease travel restrictions by waiving the quarantine requirement for vaccinated residents who received their second vaccine dose at least 14 days before arrival. The program still required a polymerase chain reaction (PCR) test to be performed on each passenger on arrival at Hamad International Airport, Qatar’s international travel gate. We investigated the incidence of PCR-positive test results in arriving passengers.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Laith J. Abu-Raddad, PhD, Weill Cornell Medicine–Qatar, Qatar Foundation–Education City, PO Box 24144, Doha, Qatar (email@example.com).
Accepted for Publication: June 1, 2021.
Published Online: June 9, 2021. doi:10.1001/jama.2021.9970
Author Contributions: Ms Chemaitelly and Dr Abu-Raddad had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.
Concept and design: Bertollini, Al Thani, Al Khal, Abu-Raddad.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Chemaitelly, Abu-Raddad.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Chemaitelly.
Obtained funding: Al Thani, Abu-Raddad.
Administrative, technical, or material support: All authors.
Supervision: Bertollini, Al Thani, Al Khal, Abu-Raddad.
Conflict of Interest Disclosures: None reported.
Disclaimer: Statements made herein are solely the responsibility of the authors.
Additional Contributions: We acknowledge the data, viral genome sequencing, and logistical efforts of the National Study Group for COVID-19 Epidemiology including Fatiha M. Benslimane, PhD, Hebah A. Al Khatib, PhD, Hanan F. Abdul Rahim, PhD, Gheyath K. Nasrallah, PhD, Houssein H. Ayoub, PhD (all with Qatar University); Peter Coyle, MD, Adeel A. Butt, MD, MS, Andrew Jeremijenko, MD, Zaina Al Kanaani, PhD, Einas Al Kuwari, MD, Anvar H. Kaleeckal, MSc, Ali Nizar Latif, MD, Riyazuddin M. Shaik, MSc (all with Hamad Medical Corporation); Patrick Tang, MD, PhD (Sidra Medicine); Mohamed Ghaith Al Kuwari, MD (Primary Health Care Corporation); and Hamad Eid Al Romaihi, MD (Ministry of Public Health, Doha, Qatar). None of these individuals were compensated for their role in the study. We also acknowledge the uncompensated administrative support of Adona Canlas, BSc (Weill Cornell Medicine–Qatar, Cornell University); and Steven Aird, PhD (unaffiliated) for compensated English editing of a draft of the manuscript. We also acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, and the Qatar Biobank for their diligent efforts and contributions to make this study possible. We are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine–Qatar. We are also grateful for the Qatar Genome Programme for supporting the viral genome sequencing.
You currently have no searches saved.